Association Between Methylmalonic Acid and Cognition: A Systematic Review and Meta-Analysis

Chao Wang¹, Ying Zhang¹, Jianbo Shu¹, Chunyu Gu¹, Yuping Yu¹ and Wei Liu³*

¹ Tianjin Pediatric Research Institute, Tianjin Children’s Hospital, Children’s Hospital of Tianjin University, Tianjin, China, ² Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China, ³ Tianjin Children’s Hospital, Children’s Hospital of Tianjin University, Tianjin, China

Background: Methylmalonic acid (MMA) is an intermediate metabolite of human body. The content of MMA in the blood of healthy people is very low, and its concentration will increase in some diseases and elderly people. Recent studies have shown that MMA has a variety of biological functions. The correlation between MMA and cognition, one of the important functions of the nervous system, is still uncertain.

Objective: Meta-analyses were performed to assess whether elevated MMA was associated with the risk of cognitive decline.

Materials and Methods: Cross-sectional studies, randomized controlled studies, and case-control studies on the relationship between MMA and cognition were obtained by searching PubMed, Web of Science, EMBASE, ProQuest, WANGFANG MED ONLINE, China National Knowledge Infrastructure (CNKI) and Chongqing VIP until May 2022. Two researchers independently selected studies according to inclusion and exclusion criteria, evaluated study quality and extracted data. Meta-analyses were performed using Review Manager 5.4 software. The sensitivity analysis of meta-analysis was performed by One by one exclusion method.

Results: A total of 11 studies were included, including six cross-sectional studies, two randomized controlled studies, and three case-control studies, with a sample of 16,533 subjects. Meta-analysis showed that there was no significant difference in cognitive level between high-level MMA subjects and low-level MMA subjects in the general population [SMD = −2.19, 95% CI (−4.76 ~ 0.38), Z = 1.67, P = 0.09]. In the population supplemented with VitB12, the increase of MMA level caused by VitB12 supplementation was not related to the change of cognition [SMD = 0.32, 95% CI (−0.19 ~ 0.84) z = 1.22, P = 0.22]. There was also no significant difference in MMA levels between patients with dementia and the control group [WMD = 20.89, 95% CI (−5.13 ~ 46.92), z = 1.57, P = 0.12].
INTRODUCTION

Cognitive impairment is one of the common manifestations of abnormal development or dysfunction of the nervous system. It is often seen in neurological, mental and elderly diseases, such as depression, neurasthenia and Alzheimer’s disease. Vitamin B12 (VitB12) has long been considered as a nutrient necessary for the development and functional maintenance of the nervous system. A variety of evidence-based medicine research results show that the lack of VitB12 can lead to a variety of neuropsychiatric diseases, including the decline of cognitive level (1).

In addition to VitB12 itself, methylmalonic acid (MMA), a binary acid in VitB12 related metabolic pathway, is the most commonly used marker in the medical detection of human VitB12, even more than VitB12 itself, this is because the serum VitB12 level with a certain lag is not consistent with the intracellular VitB12 state, while MMA can more quickly reflect the real demand state of human body for VitB12 (2, 3). In previous studies, MMA exists only as a metabolite or marker, and there are few research on the function of MMA itself. However, the latest researches show that MMA may have important biological functions. For example, one study has confirmed with sufficient and detailed evidence that MMA gradually accumulated with aging can induce transcriptional reprogramming by promoting SRY-box transcription factor 4 (SOX4) gene expression and promote tumor progression and invasion (4). Metabolism of cobalamin associated B protein (MMAB) can inversely regulate cholesterol metabolic balance through MMA (5). MMA can also damage the respiration of SH-SY5Y cells and reduce the expression of a variety of differentiation markers (6). The association between VitB12 and cognitive function has been proven in many studies, in some of which serum MMA completely represented VitB12 levels (7). Therefore, it cannot be ruled out that MMA is one of the factors that really play a role. In the research on the relationship between VitB12 and cognition, MMA was also detected as one of a variety of VitB12 markers, some of which also proved that single factor MMA was related to the decline of cognitive level (2), while some other study results showed that there was no correlation between them (8). Previous meta-analysis showed that total serum homocysteine (tHcy), another important marker of VitB12, was positively correlated with the incidence of dementia (9). The aim of this systematic review and meta-analysis was to evaluate the influence of MMA as a single factor on cognition, and draw a more objective conclusion.

Conclusion: In the general population, whether VitB12 is supplemented or not, there is no correlation between the increase of MMA level and the decrease of cognitive level. In dementia diseases, the level of MMA did not change significantly. High levels of MMA may not be a risk factor for cognitive impairment. The exact relationship between MMA and cognition needs further research.

Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021266310], identifier [CRD42021266310].

Keywords: methylmalonic acid (MMA), cognition, meta-analysis, vitamin B12, dementia
TABLE 1 | PICOS criteria for inclusion and exclusion of studies.

| Parameter       | Description                                                                 |
|-----------------|-----------------------------------------------------------------------------|
| Population      | General population, population with VitB12 deficiency and patients with dementia |
| Intervention/exposure | Elevated serum MMA levels                                                    |
| Comparison      | Population with lower serum MMA levels or randomized control population or healthy control population |
| Outcome         | Change in cognitive levels and in morbidity of dementia                      |
| Study design    | Cross-sectional studies, randomized controlled studies and case-control studies |

and standard deviation) for treatment and control groups, disease type, and MMA levels in case group and control group.

Quality Assessment
Two authors independently assessed the quality of the included studies. Cross-sectional studies were accessed using the Agency for Healthcare Research and Quality (AHRQ) assessment scale which includes 11 items, with a total of 11 scores. 0 ~ 3 scores, 4 ~ 7 scores, and 8 ~ 11 scores are low, medium, and high quality in turn. The risk of bias of randomized controlled studies was assessed using the Cochrane handbook which had seven scores items each of which was classified as low risk, high risk, and unknown. The quality of included case-control studies was assessed using the Newcastle–Ottawa Scale with a total score of 9 and those with ≥6 were regarded as high-quality study. Any difference in the scores between the two authors was assessed by the third author.

Data Analysis
RevMan 5.4.1 software was used for statistical analysis. All outcomes of included studies were calculated as standardized mean difference (SMD) or weighted mean difference (WMD) with 95% confidence interval (95% CI). P < 0.05 indicates that the difference was statistically significant. The heterogeneity among studies was assessed with Q-test and I² statistic. I² below 25% was considered as low heterogeneity, 25 ~ 50% as medium heterogeneity, 50 ~ 75% as high heterogeneity, and more than 75% was considered as very high heterogeneity. If P > 0.1 and I² < 50%, it was considered that there was no statistical heterogeneity, and a fixed-effects model was used for meta-analysis; otherwise, a random-effects model was used for analysis. Subgroup analysis was used to explore the source of heterogeneity if necessary. The potential bias of included studies was analyzed by funnel chart. One by one exclusion method was used for sensitivity analysis.

RESULTS
Search Results
1,680 records were retrieved according to the inclusion and exclusion criteria above. Through duplicate check, study design screening, abstract screening and full-text screening, 1,669 records were eliminated, and finally 11 studies were selected for meta-analysis, including six cross-sectional studies, two randomized controlled studies, and three case-control studies (Figure 1), with a total of 16,533 subjects.

Except for one of the studies involving children aged 6~11 months, the subjects in the other studies were adults aged ≥19 years, and most of them were elderly. All of the above study populations were from European and North American countries except one study from Nepal. The mean and standard deviation of cognitive score or plasma MMA level could be extracted from the 11 studies, and the cognitive scoring systems used in the included cross-sectional and randomized controlled studies were not identical (Table 2). The quality of the included study is of medium or high level (Tables 3, 4 and Figure 2).

Association Between Methylmalonic Acid and Cognition in Cross-Sectional Studies of the General Population
A total of 15,554 subjects were enrolled from the six cross-sectional studies, with an age distribution of ≥19 years. Random effect model was applied due to the statistical heterogeneity among the included studies (I² = 100%). Meta-analysis showed that increased MMA level was not associated with decreased cognitive level in the general population without intervention, the difference was not statistically significant [SMD = −2.19, 95% CI (−4.76 ~ 0.38), Z = 1.67, P = 0.09; Figure 2]. Cochrane funnel chart was used to visually evaluate the bias of the studies. The funnel chart showed incomplete symmetry suggesting that bias may exist (Figure 3). In the sensitivity analysis with one-by-one exclusion method, the results were: SMD = −1.16, 95% CI (−1.82...
TABLE 2 | General characteristics of the included 11 studies.

| Author (year) | Area/Country | Study design          | Age          | Sample size (female) | Cognitive scoring system/Disease |
|---------------|--------------|-----------------------|--------------|----------------------|----------------------------------|
| Kobe et al. (11) | Berlin and Frankfurt, Germany | Cross-sectional study | 50–80 years | 100 (52) | MMSE |
| Lidballe et al. (12) | Oxfordshire, United Kingdom | Cross-sectional study | ≥75 years | 163 (127) | MMSE |
| Bailey et al. (13) | United States | Cross-sectional study | ≥19 years | 11119 (5463) | DSC-based comprehensive scoring |
| Clarke et al. (14) | Oxford, United Kingdom | Cross-sectional study | ≥65 years | 1020 (?) | MMSE |
| Garcia et al. (15) | Ontario, Canada | Cross-sectional study | ≥65 years | 281 (?) | Stroop |
| Wright et al. (16) | Manhattan, New York, United States | Cross-sectional study | ≥40 years | 2871 (?) | MMSE |
| Strand et al. (17) | Bhakapur, Nepal | Randomized controlled study | 6–11 months | 572 (?) | Bayley-III |
| Eussen et al. (18) | Netherlands | Randomized controlled study | ≥70 years | 100 (?) | Stroop |
| Miller et al. (19) | United States | Case-control study | Patients: 79 ± 7 years Control: 75 ± 6 years | 54 (33) | Alzheimer’s disease |
| Nilsson et al. (20) | Sweden | Case-control study | Patients: 77.3 ± 8.6 years Control: 76.1 ± 8.0 years | 130 (?) | Dementia |
| Lehmann et al. (21) | Sweden | Case-control study | 71.5 ± 8.8 years | 123 (73) | Senile dementia of the Alzheimer type |

?; unknown; MMSE, Mini-mental State Examination; DSC, Digit Symbol-Coding test scale; Stroop, Stroop neuropsychological screening scale.

Association Between Methylmalonic Acid and Cognition in Case-Control Studies of Population Supplemented With Vitamin B12

The total number of subjects in the two randomized controlled studies was 672, including children aged 6–11 months in one study and elderly people over 70 years in the other study. The statistical heterogeneity $I^2$ of the two studies was 83%, so the random effect model was used. Meta-analysis showed that in population supplemented with VitB12, the increase of MMA level was not related to the decrease of cognitive level, the difference was not statistically significant [SMD = 0.32, 95% CI (−0.19 ~ 0.84), $Z = 1.22, P = 0.22$; Figure 4]. In the sensitivity analysis, the difference became statistically significant after removing the research of Eussen, S. J., etc. [SMD = 0.62, 95% CI (0.22 ~ 1.03), $Z = 3.03, P = 0.002$]. The results remained unchanged after removing another study.

Association of Methylmalonic Acid With Cognition in Case-Control Studies of Dementia Diseases

Three hundred seven subjects in the three case-control studies were included in the analysis, all of whom were elderly. The statistical heterogeneity $I^2$ of the three studies was 47%, so the fixed effect model was used for analysis. The results showed that there was no significant difference in the level of MMA between the disease group and the healthy control group [WMD = 20.89, 95% CI (−5.13 ~ 46.92), $Z = 1.57, P = 0.12$; Figure 5]. In the sensitivity analysis, when the research of Miller J. W., etc., was removed, the difference became significant [WMD = 35.66, 95% CI (3.68 ~ 67.65), $Z = 2.19, P = 0.03$]. The results remained unchanged after removing the other two studies one by one. Sensitivity analysis showed that the stability of the above three meta-analysis was not sufficient.

DISCUSSION

Vitamin B12 plays an important role in the development and functional maintenance of the nervous system, and its strong correlation with cognitive function has also been confirmed in most studies. However, the metabolic regulation pathways of human body are staggered and complex, a nutrient deficiency can cause a variety of dysfunction, and a dysfunction can also be caused by different nutrients or intermediate abnormal metabolites. VitB12 is known to play a role in the form of coenzyme in human body, and its lack can cause abnormal accumulation of intermediate metabolites. The deep-seated causes of cognitive impairment are still unknown, and the correlation or even causality between the above metabolites and the formation of cognitive impairment cannot be ruled out.

A large-scale study based on the general population pointed out that the concentration of serum MMA began to rise at the age of 18–20, and this state will continue with age (22). Therefore, it is of great significance to explore the biological function and health impact of this metabolite. In this study, the relationship between MMA and cognition was comprehensively evaluated by meta-analysis for the first time. The final analysis results of this study showed that the increase of MMA serum concentration was not related to the decline of cognitive level, whether in the general non-intervention population or the population supplemented with VitB12, and there was no significant increase in MMA level in dementia diseases characterized by severe cognitive impairment.
MMA is negatively correlated with global cognition and episodic memory (26). High levels of MMA in community-based studies were not associated with brain volume loss but with cognitive impairment (27). Epidemiological studies have shown that high levels of MMA in circulatory system are associated with decreased cognitive function. In a longitudinal study conducted in the United Kingdom, the concentration of serum MMA increased from 0.25 to 0.50 µmol/L is associated with a 50% accelerated decline in cognitive level (28). In a multivariate analysis, a mixed effect model was used to test the association between each biochemical marker and cognition, and only MMA was associated with lower global cognitive score. In the 6-year follow up, the higher the MMA concentration, the faster the cognitive decline (29). Two other studies on the elderly in the community found that the increase of MMA concentration was related to cognitive impairment, but not to plasma VitB12 (30). High serum MMA is common in the elderly and negatively correlated with motor and cognitive performance (31). Increased MMA has also been confirmed to be associated with cognitive impairment in elderly stroke survivors (32). Some studies have concluded that the correlation between serum MMA and tHcy and cognitive impairment is stronger than VitB12 although the relationship between VitB12 and cognition is well known by researchers (33).

Increased MMA levels are also associated with other neurological diseases (34). The occurrence of high MMA (>360 nmol/L) in dementia patients was significantly higher than that in the control group (35). VitB12 deficiency defined by increased MMA levels is associated with an increased risk of dementia diagnosis (36). Studies have shown that the increase of MMA and tHcy, rather than the level of plasma VitB12, is related to pathologically confirmed Alzheimer's disease (30). In a case-control study of Alzheimer's disease, MMA levels were higher in the case group than in the control group ($P = 0.027$) (37). While the proportion of cognitive impairment in the population with increased plasma MMA is increased, the prevalence of depression is also quite high (38). In cblC disease characterized by increased MMA levels, some of the detected protein changes were similar to those in Alzheimer's disease (39).

### TABLE 3 | Quality assessment of included 6 cross-sectional studies with Agency for Healthcare Research and Quality (AHRQ) assessment tool.

| Study | (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | (9) | (10) | (11) | Total score |
|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------------|
| (11)  | Yes | Yes | No  | UC  | UC  | Yes | Yes | Yes | Yes | Yes | No  | 7           |
| (12)  | Yes | Yes | Yes | Yes | UC  | Yes | Yes | Yes | Yes | Yes | UC  | 8           |
| (13)  | Yes | Yes | Yes | Yes | UC  | Yes | Yes | Yes | Yes | Yes | No  | 8           |
| (14)  | Yes | Yes | Yes | Yes | No  | UC  | Yes | Yes | Yes | Yes | No  | 8           |
| (15)  | Yes | Yes | Yes | Yes | UC  | Yes | Yes | Yes | No  | Yes | No  | 8           |
| (16)  | Yes | Yes | Yes | Yes | Yes | UC  | Yes | No  | Yes | No  | No  | 8           |

UC: Unclear.

(1) Define the source of information (survey, record review).
(2) List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications.
(3) Indicate time period used for identifying patients.
(4) Indicate whether or not subjects were consecutive if not population-based.
(5) Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants.
(6) Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements).
(7) Explain any patient exclusions from analysis.
(8) Describe how confounding was assessed and/or controlled.
(9) If applicable, explain how missing data were handled in the analysis.
(10) Summarize patient response rates and completeness of data collection.
(11) Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained.

### TABLE 4 | Quality assessment of included 3 case-control studies with Newcastle–Ottawa Scale.

| Study | Selection | Comparability | Exposure | Total score |
|-------|-----------|---------------|----------|-------------|
|       | 1 | 2 | 3 | 4 | 1 | 2 | 3 | | |
| (19)  | * | * | * | * | * | - | - | * | * | 9   |
| (20)  | * | * | * | - | * | * | - | * | * | 8   |
| (21)  | * | * | - | * | * | - | * | * | * | 6   |

–, no score. *, one score.
Methylmalonic acid may have neurotoxicity, which is supported by its tissue distribution characteristics. Cerebrospinal fluid MMA correlated with serum MMA with an r of 0.69, \( P < 0.0001 \), and mean cerebrospinal fluid MMA was 170\% of mean serum measurement. The levels of several similar analytes, such as VitB12, holotranscobalamin and tHcy, in cerebrospinal fluid were much lower than in serum (40). Study has shown that higher substantia nigra echogenic area was associated with higher plasma concentrations of MMA (41). High concentrations of MMA are also associated with more severe white matter lesions (WML), although this association is statistically significant only in periventricular WML (42).

Funnel plot shows that there may be serious bias in this meta-analysis. In the sensitivity analysis, after removing one of the studies of the three meta-analyses separately, statistically significant differences in cognitive scores were detected, indicating that the stability of the results of this study is not sufficient. This may be related to the special data extraction method. Up to now, there are few population cohort or case-control studies with MMA as the risk factor alone, so the data of this study were mainly extracted from the researches on the relationship between B vitamins and their multiple markers and diseases, which made the grouping criteria of the original subjects by MMA level not very consistent, this may make the data unable to reflect the real situation to a certain extent and affect the accuracy of the results.

To sum up, the results of this meta-analysis show that elevated MMA is not associated with cognitive decline. Available trials have limitation in the original data. Further well-designed large sample prospective studies and basic mechanism researches are needed.
needed so as to provide a solid and reliable basis for the prevention and treatment of cognitive diseases.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

WL and CW contributed to conception and design of the study. CW and YZ search the databases and performed the statistical analysis. CW, YZ, YY, and JS did the screening of abstracts and full manuscript for inclusion. CW and JS wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

**FUNDING**

This work was supported by the Tianjin Health Science and Technology Project (grant numbers: ZC20123, ZC20120, and KJ20039), Public Health and Technology Project of Tianjin (grant number TJWJ2021ZD007), and Natural Science Foundation of Tianjin (grant number: 21JCZDJC00390).

**REFERENCES**

1. Nalder L, Zheng B, Chiandet G, Middleton LT, de Jager CA. Vitamin B12 and folate status in cognitively healthy older adults and associations with cognitive performance. *J Nutr Health Aging.* (2021) 25:287–94. doi: 10.1007/s12603-020-1489-y
2. Kvestad T, Hysing M, Shrestha M, Ulak M, Thorne-Lyman AL, Henjum S, et al. Vitamin B-12 status in infancy is positively associated with development and cognitive functioning 5 y later in nepalese children. *Am J Clin Nutr.* (2017) 105:1122–31. doi: 10.3945/ajcn.164.144931
3. Doets EL, Ueland PM, Tell GS, Vollset SE, Nygård OK, Van’t Veer P, et al. Interactions between plasma concentrations of folate and markers of vitamin B(12) status with cognitive performance in elderly people not exposed to folic acid fortification: the Hordaland health study. *Br J Nutr.* (2014) 111:1085–95. doi: 10.1017/S000711451300336X
4. Gomes AP, Ilter D, Low V, Endress JE, Fernández-Garcia J, Rosenzweig A, et al. Age-induced accumulation of methylmalonic acid promotes tumour progression. *Nature.* (2020) 585:283–7. doi: 10.1038/s41586-020-2630-0
5. Goedeke L, Canfrán-Duque A, Rollann N, Chaube B, Thompson BM, Lee RG, et al. Methylmalonic acid compromises respiration and reduces the expression of differentiation markers of SH-SY5Y human neuroblastoma cells. *Nat Commun.* (2021) 12:6448. doi: 10.1038/s41467-021-26787-7
6. da Costa RT, Dos Santos MB, Silva L, de Almeida RP, Teruel MS, Carretierro DC, et al. Methylmalonic acid compromises respiration and reduces the expression of differentiation markers of SH-SYSY human neuroblastoma cells. *ACS Chem Neurosci.* (2021) 12:2608–18. doi: 10.1021/acschemneuro.1c00119
7. Boumenna T, Scott TM, Lee JS, Palacios N, Tucker KL. Folate, vitamin B-12, and cognitive function in the Boston Puerto Rican health study. *Am J Clin Nutr.* (2020) 113:179–86. doi: 10.1093/ajcn/qnx293
8. Nerk E, Refsum H, Bjelland I, Drevon CA, Tell GS, Ueland PM, et al. Plasma free choline, betaine and cognitive performance: the Hordaland health study. *Br J Nutr.* (2013) 109:511–9. doi: 10.1017/S0007114512001249
9. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. *Alzheimers Dement.* (2011) 7:412–7. doi: 10.1016/j.jalz.2010.08.234
10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Res Esp Cardiol (Engl Ed).* (2021) 74:790–9. doi: 10.1161/JAHA.121.001169
11. Købe T, Witte AV, Schnelle A, Grittner U, Tesky VA, A, Pantel J, et al. Vitamin B12 status and rate of brain volume loss in community-dwelling patients with mild cognitive impairment. *Am J Clin Nutr.* (2016) 103:1045–54. doi: 10.3944/ajcn.115.116970
12. Lildbaalle DL, Fedosov S, Sherliker P, Hin H, Clarke R, Nexo E. Association of cognitive impairment with combinations of vitamin B12-related parameters. *Clin Chem.* (2011) 57:1436–43. doi: 10.1373/clinchem.2011.165944
13. Bailey RL, Carmel R, Green R, Pleifler CM, Cogswell ME, Osterloh JD, et al. Monitoring of vitamin B-12 nutritional status in the United States by using plasma methylmalonic acid and serum vitamin B-12. *Am J Clin Nutr.* (2011) 94:552–61. doi: 10.3944/ajcn.111.015222
14. Clarke R, Birks J, Nexo E, Ueland PM, Schneede J, Scott J, et al. Low vitamin B-12 status and risk of cognitive decline in older adults. *Am J Clin Nutr.* (2007) 86:1384–91. doi: 10.1093/ajcn/86.5.1384
15. Garcia AA, Haron Y, Evans LR, Smith MG, Freedman M, Roman GC. Metabolic markers of cobalamin deficiency and cognitive function in normal older adults. *J Am Geriatr Soc.* (2004) 52:66–71. doi: 10.1111/j.1532-5414.2004.00512.x
16. Wright CB, Lee HS, Paik MC, Stabler SP, Allen RH, Sacco RL. Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan study. *Neurology.* (2004) 63:234–60. doi: 10.1212/01.wnl.0000129896.19019.5d
17. Strand TA, Ulak M, Hysing M, Ranjitkar S, Kvestad I, Shrestha M, et al. Effects of vitamin B12 supplementation on neurodevelopment and growth in nepalese infants: a randomized controlled trial. *PLoS Med.* (2020) 17:e1003430. doi: 10.1371/journal.pmed.1003430
18. Eussen SJ, de Groot LC, Joosten LW, Bloo RJ, Clarke R, Ueland PM, et al. Effect of oral vitamin B12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. *Am J Clin Nutr.* (2006) 84:361–70. doi: 10.1093/jcnn/84.1.361
19. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. *Neurology.* (2002) 58:1471–5. doi: 10.1212/wnl.58.10.1471
20. Nilsson K, Gustafson I, Hultberg B. The plasma homocysteine concentration is better than that of serum methylmalonic acid as a marker for sociopsychological performance in a psychogeriatric population. *Clin Chem.* (2006) 46:691–6. doi: 10.1093/clinchem/hvi019
21. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. *Dement Geriatr Cogn Disord.* (1999) 16:12–20. doi: 10.1159/000017092
22. Ganji V, Kafai MR. Population reference values for serum methylmalonic acid concentrations and its relationship with age, sex, race-ethnicity, supplemental use, kidney function and serum vitamin B12 in the post-folic acid fortification period. *Nutrients.* (2018) 10:74. doi: 10.3390/nu10010074
23. Doets EL, van Wijngaarden JP, Szczecinska A, Dullemeijer C, Souverein OW, Dhonukhs-Rutten RA, et al. Vitamin B12 intake and status and cognitive function in elderly people. *Epidemiol Rev.* (2013) 35:2–21. doi: 10.1093/epirev/mxx003
24. Varvogli L, Repetto GM, Waisbren SE, Levy HL. High cognitive outcome in an adolescent with mut- methylmalonic acidemia. *Am J Med Genet.* (2000) 96:192–5. doi: 10.1002/(SICI)1096-8628(20000403)96:3.CO;2-A
25. Sniderman LC, Lambert M, Giguère A, Auray-Blais C, Lemieux B, Lafraimboise R, et al. Outcome of individuals with low-moderate methylmalonic aciduria detected through a neonatal screening program. *J Pediatr.* (1999) 133:675–80. doi: 10.1016/s0022-3476(99)70280-5
26. Vogiatzoglou A, Smith AD, Nurk E, Drevon CA, Ueland PM, Vollset SE, et al. Cognitive function in an elderly population: interaction between vitamin B12 status, depression, and apolipoprotein E ε4: the Hordaland Homocysteine Study. *Psychosom Med.* (2013) 75:20–9. doi: 10.1097/Psy.0b013e3182761b6c
27. Vogiatzoglou A, Refsum H, Johnston C, Smith SM, Bradley KM, de Jager C, et al. Vitamin B12 status and rate of brain volume loss in community-dwelling...
elderly. *Neurology.* (2008) 71:826–32. doi: 10.1212/01.wnl.0000325581.26991.f2

28. Ganji V, Kafai MR. Population prevalence, attributable risk, and attributable risk percentage for high methylmalonic acid concentrations in the post-folic acid fortification period in the US. *Nutr Metab (Lond).* (2012) 9:2. doi: 10.1186/1743-7075-9-2

29. Tangney CC, Tang Y, Evans DA, Morris MC. Biochemical indicators of vitamin B12 and folate insufficiency and cognitive decline. *Neurology.* (2009) 72:361–7. doi: 10.1212/01.wnl.0000341272.48617.b0

30. Smith AD, Refsum H. Vitamin B-12 and cognition in the elderly. *Am J Clin Nutr.* (2009) 89:1155–62. doi: 10.1093/ajcn/81.5.1155

31. Pascoe MC, Linden T. Folate and MMA predict cognitive impairment in elderly stroke survivors: a cross sectional study. *Psychiatry Res.* (2016) 243:49–52. doi: 10.1016/j.psychres.2016.06.008

32. Stein J, Geisel J, Obied R. Association between neuropathy and B-vitamins: a systematic review and meta-analysis. *Eur J Neurol.* (2021) 28:2054–64. doi: 10.1111/ene.14786

33. Bednarska-Makaruk M, Graban A, Sobczyńska-Malefora A, Harrington DJ, Mitchell M, Voong K, et al. Homocysteine metabolism and the associations of global DNA methylation with selected gene polymorphisms and nutritional factors in patients with dementia. *Exp Gerontol.* (2016) 81:83–91. doi: 10.1016/j.exger.2016.05.002

34. O'Leary F, Allman-Farinelli M, Samman S. Vitamin B12 status, cognitive decline and dementia: a systematic review of prospective cohort studies. *Br J Nutr.* (2012) 108:1948–61. doi: 10.1017/S0007114512004175

35. Refsum H, Smith AD. Low vitamin B-12 status in confirmed Alzheimer’s disease as revealed by serum holotranscobalamin. *J Neurol Neurosurg Psychiatry.* (2003) 74:959–61. doi: 10.1136/jnnp.74.7.959

36. Hvas AM, Juul S, Lauritzen L, Nexø E, Ellegaard J. No effect of vitamin B-12 treatment on cognitive function and depression: a randomized placebo controlled study. *J Affect Disord.* (2004) 81:269–73. doi: 10.1016/S0165-0327(03)00169-1

37. Hannibal L, DiBello PM, Yu M, Miller A, Wang S, Willard B, et al. The MMA/HC proteome: hallmarks of functional cobalamin deficiency in humans. *Mol Genet Metab.* (2011) 103:226–39. doi: 10.1016/j.ymgme.2011.03.008

38. Christine CW, Auinger P, Saleh N, Tian M, Bottiglieri T, Arning E, et al. Relationship of cerebrospinal fluid Vitamin B12 status markers with Parkinson’s disease progression. *Mov Disord.* (2020) 35:1466–71. doi: 10.1002/mds.28073

39. Hvas AM, Juul S, Lauritzen L, Nexø E, Ellegaard J. No effect of vitamin B-12 treatment on cognitive function and depression: a randomized placebo controlled study. *J Affect Disord.* (2004) 81:269–73. doi: 10.1016/S0165-0327(03)00169-1

40. Obeid R, Schadt A, Dillmann U, Kostopoulos P, Fassbender K, Herrmann W. Methylation status and neurodegenerative markers in Parkinson disease. *Clin Chem.* (2009) 55:1852–60. doi: 10.1373/clinchem.2009.129211

41. de Lau LM, Smith AD, Refsum H, Johnston C, Bretelet MM. Plasma vitamin B12 status and cerebral white-matter lesions. *J Neurol Neurosurg Psychiatry.* (2009) 80:149–57. doi: 10.1136/jnnp.2008.149286

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Wang, Zhang, Sha, Gu, Yu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*